1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

AML - 424

Dual Targeting of FLT3 Signaling and BCL2 Dependency by Venetoclax in ATO-Resistant FLT3-ITD Acute Promyelocytic Leukemia

Deepshikha Dutta

Poster Presenter: Deepshikha Dutta

$Thumbnail for Durability of Response, Mechanisms of Resistance, and Retreatment Outcomes Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review$

MM - 453

Durability of Response, Mechanisms of Resistance, and Retreatment Outcomes Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review

Mahboob Younus Shaik

Poster Presenter: Mahboob Younus Shaik

SOHO 2026 Annual Meeting

Posters by Title

Dual Targeting of FLT3 Signaling and BCL2 Dependency by Venetoclax in ATO-Resistant FLT3-ITD Acute Promyelocytic Leukemia

Durability of Response, Mechanisms of Resistance, and Retreatment Outcomes Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review

Durable Clinical Benefit of B-Cell Maturation Antigen (BCMA)-Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-8 Long-Term Responder (LTR) Analysis

Durable Complete Remission Following HMA Therapy in Higher-Risk MDS Is Not Fully Determined by Baseline Disease Biology

Duration of Minimal Residual Disease Negativity Predicts Durable Disease Control in Multiple Myeloma: A Meta-Analysis of 8900 Patients

Early Acute Kidney Injury and Mortality in Critically Ill Patients With Multiple Myeloma: A Two-Cohort Study

Early CD26? Leukemic Stem Cell Kinetics Can Predict Suboptimal Molecular Response and Switching TKIs during Chronic-Phase CML Therapy

Early Cytarabine Escalation Does Not Improve Short-Term Outcomes Compared With Hydroxyurea-Only Cytoreduction in Hyperleukocytic Acute Myeloid Leukemia: A Real-World Propensity-Matched Analysis

Early Experience With Glofitamab (Glofit) Plus Polatuzumab Vedotin (Pola) As Bridging Therapy (BT) Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)